Executive Director - Drug Product
Novo Nordisk
Basking Ridge, New Jersey
Anjali Agrawal, Ph.D. Executive Director, CMC and Product Supply, Novo Nordisk Inc.
Anjali Agrawal is an executive director in CMC and product supply organization at Novo Nordisk. She is a strategic Pharmaceutical Executive with more than 25 years’ experience in leading global product development functions and project teams. She has deep technical, strategic and operational leadership expertise in development and commercialization of oral and parenteral product portfolio consisting of NCE’s, product line extensions, and in-licensed assets for adult and pediatric patients in several disease areas.
She successfully established global DP group, facilities, structure, operating models, business processes, and CRO/CDMO network at Forma Therapeutics, BMS, Celgene, Boehringer Ingelheim, Pfizer, and Wyeth. Anjali broadened her impact on drug development through leadership roles in global project management, CMC project management, commercial supply management, and alliance management. She is an innovative thought leader with a proven track record in designing novel processes, platform formulations, and material sparing predictive methodologies that streamlined DP development and accelerated commercialization of innovative medicines. She has a passion to develop palatable pediatric dosage form and established enterprise strategy for oral and parenteral pediatric products at several companies. She is an active member of AAPS, IQ Pediatric, and EuPFI consortia.
Disclosure information not submitted.
How to Resolve Dilemma of Selecting Excipients for Pediatric Products?
Tuesday, November 11, 2025
9:30 AM - 10:00 AM CT